Psoriasis: New insight about pathogenesis, role of barrier organ integrity, NLR/CATERPILLER family genes and microbial flora

Journal of Dermatology

Volumn 39, Issue 9, 2012, Pages 752-760

  Mattozzi, Carlo ^a   Richetta, Antonio G ^a   Cantisani, Carmen ^a   MacAluso, Laura ^a   Calvieri, Stefano ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

barrier organs; Crohn's disease; inflammation; NLR; psoriasis

Indexed keywords

BETA DEFENSIN 2; CASPASE 5; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CASPASE RECRUITMENT DOMAIN PROTEIN 4; CASPASE RECRUITMENT DOMAIN SIGNALING PROTEIN; CRYOPYRIN; DNA; GAMMA INTERFERON; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 12P40; INTERLEUKIN 1BETA CONVERTING ENZYME; INTERLEUKIN 23 RECEPTOR; INTERLEUKIN 8; LEUCINE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NEURONAL APOPTOSIS INHIBITORY PROTEIN; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 22; OVALBUMIN; STAT4 PROTEIN; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

BACTERIAL COLONIZATION; CAMPYLOBACTER; CHROMOSOME 6; CROHN DISEASE; DNA SEQUENCE; ENTEROPATHY; ENVIRONMENTAL FACTOR; ESCHERICHIA COLI; GENE; HOMEOSTASIS; HUMAN; INFLAMMATORY DISEASE; INNATE IMMUNITY; INSULIN DEPENDENT DIABETES MELLITUS; INTERFERON PRODUCTION; INTESTINE FLORA; MALASSEZIA FURFUR; MICROFLORA; MULTIGENE FAMILY; NONHUMAN; PATHOGENESIS; PSORIASIS; REVIEW; RISK FACTOR; SALMONELLA; SARCOIDOSIS; SIGNAL TRANSDUCTION; STREPTOCOCCUS PYOGENES; SYSTEMIC LUPUS ERYTHEMATOSUS; YERSINIA;

CROHN DISEASE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MODELS, BIOLOGICAL; MULTIGENE FAMILY; PSORIASIS; SKIN;

EID: 84865644176     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/j.1346-8138.2012.01606.x     Document Type: Review

References (90)

1. Salgo R, Thaçi D,. Treatment of moderate-to-severe plaque psoriasis. G Ital Dermatol Venereol 2009; 144 (6): 701-711.
2. Henseler T, Christophers E,. Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol 1985; 13: 450-456.
3. Elder JT, Bruce AT, Gudjonsson JE, et al. Molecular dissection of psoriasis: integrating genetics and biology. J Invest Dermatol 2010; 130 (5): 1213-1226.
4. Lima HC, Kimball AB,. Targeting IL-23: insights into the pathogenesis and the treatment of psoriasis. Indian J Dermatol 2010; 55 (2): 171-175.
5. Monteleone G, Pallone F, MacDonald TT, et al. Psoriasis: from pathogenesis to novel therapeutic approaches. Clin Sci (Lond) 2010; 120 (1): 1-11.
6. Jensen JM, Proksch E,. The skin's barrier. G Ital Dermatol Venereol 2009; 144 (6): 689-700.
7. Ting JP, Davis BK,. CATERPILLER: a novel gene family important in immunity, cell death, and diseases. Annu Rev Immunol 2005; 23: 387-414.
8. Irvine EJ, Marshall JK,. Increased intestinal permeability precedes the onset of Chron's disease in subject with familial risk. Gastroenterology 2000; 119: 1740-1744.
9. Girardin SE, Boneca IG, Viala J, et al. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem 2003; 278: 8869-8872.
10. Petnicki-Ocwieja T, Hrncir T, Liu Y, et al. Nod2 is required for the regulation of commensal microbiota in the intestine. Proc Natl Acad Sci 2009; 106 (37): 15813-15818.
11. Kobayashi KS, Chamaillard M, Ogura Y, et al. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science 2005; 307: 731-734.
12. Pauleau AL, Murray PJ., Role of Nod2 in the response of macrophages to toll-like receptor agonists. Mol Cell Biol 2003; 23: 7531-7539.
13. Watanabe T, Kitani A, Murray PJ, et al. Nucleotide binding oligomerization domain 2 deficiency leads to dysregulated TLR2 signaling and induction of antigen-specific colitis. Immunity 2006; 25 (3): 473-485.
14. Hisamatsu T, Suzuki M, Reinecker HC, Nadeau WJ, McCormick BA, Podolsky DK,. CARD15/NOD2 functions as antibacterial factor in human intestinal epithelial cells. Gastroenterology 2003; 124: 993-1000.
15. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001; 411: 603-606.
16. Davis CP,. Normal flora. In:, Baron S, ed. Medical Microbiology, 4th edn, Chapter 6. Galveston, TX: University of Texas Medical Branch at Galveston, 1996.
17. Schultz M, Tonkonogy SL, Sellon RK, et al. IL-2-deficient mice raised under germfree conditions develop delayed mild focal intestinal inflammation. Am J Physiol 1999; 276: 1461-1472.
18. Ting JP, Kastner DL, Hoffman HM,. Caterpillers, pyrin and hereditary immunological disorders. Nat Rev Immunol 2006; 6: 183-195.
19. Harton JA, Linhoff MW, Zhang J, et al. Cutting edge: CATERPILLER: a large family of mammalian genes containing card, pyrin, nucleotide-binding, and leucine-rich repeat domains. J Immunol 2002; 169: 4088-4093.
20. Steimle V, Otten LA, Zufferey M, et al. Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome). Cell 1993; 75: 135-146.
21. Hysi P, Kabesch M, Moffatt MF, et al. Nod1 variation, immunoglobulin E and asthma. Hum Mol Genet 2005; 14: 935-941.
22. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Chron disease. Nature 2001; 411: 599-603.
23. Miceli-Richard C, Lesage S, Rybojad M, et al. CARD15 mutations in Blau syndrome. Nat Genet 2001; 29: 19-20.
24. Lich JD, Ting JP-Y,. CATERPILLER (NLR) Family members as positive and negative regulators of inflammatory responses. Proc Am Thorac Soc 2007; 4: 263-266.
25. Zaki MH, Lamkanfi M, Kanneganti TD,. The Nlrp3 inflammasome: contributions to intestinal homeostasis. Trends Immunol 2011; 32 (4): 171-179.
26. Day TG, Ramanan AV, Hinks A, et al. Autoinflammatory genes and susceptibility to psoriatic juvenile idiopathic arthritis. Arthritis Rheum 2008; 58 (7): 2142-2146.
27. Agostini L, Martinon F, Burns K, et al. NALP3 forms an IL-1β-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 2004; 20: 319-325.
28. Lich JD, Williams KL, Moore CB, et al. Monarch-1 suppresses non-canonical NF-ÎB activation and p52-dependent chemokine expression in monocytes. J Immunol 2007; 178: 1256-1260.
29. Schreiber S, Rosenstiel P, Albrecht M, et al. Genetics of Crohn disease, an archetypal inflammatory barrier disease. Nat Rev Genet 2005; 6 (5): 376-388.
30. Becker KG, Simon RM, Bailey-Wilson JE, et al. Clustering of non-major histocompatibility complex susceptibility candidate loci in human autoimmune diseases. Proc Natl Acad Sci USA 1998; 95 (17): 9979-9984.
31. Nair R, Henseler T, Jenisch S, et al. Evidence for two psoriasis susceptibility loci (HLA and 17q) and two novel candidate regions (16q and 20p) by genome-wide scan. Hum Mol Genet 1997; 6: 1349-1356.
32. Lee F, Bellary S, Francis C,. Increased occurrence of psoriasis in patients with Crohn's disease and their relatives. Am J Gastroenterol 1990; 85: 962-963.
33. Inohara N, Ogura Y, Chen F, et al. Human Nod1 confers responsiveness to bacterial lipopolysaccharides. J Biol Chem 2001; 276: 2551-2554.
34. Jeremias I, Kupatt C, Baumann B, et al. Inhibition of nuclear factor-ÎB activation attenuates apoptosis resistance in lymphoid cells. Blood 1998; 91: 4624-4631.
35. Rahman P, Bartlett S, Siannis F, et al. CARD15: a pleiotropic autoimmune gene that confers susceptibility to psoriatic arthritis. Am J Hum Genet 2003; 73 (3): 677-681.
36. Ho P, Bruce IN, Silman A, et al. Evidence for common genetic control in pathways of inflammation for Crohn's disease and psoriatic arthritis. Arthritis Rheum 2005; 52 (11): 3596-3602.
37. Graell E, Arostegui JI, Sanmartí R, et al. Possible association between NOD2 variants and joint surgery in psoriatic arthritis. Clin Exp Rheumatol 2010; 28 (1): 30-34.
38. Giardina E, Novelli G, Costanzo A, et al. Psoriatic arthritis and CARD15 gene polymorphisms: no evidence for association in the Italian population. J Invest Dermatol 2004; 122 (5): 1106-1107.
39. Jenisch S, Hampe J, Elder JT, et al. CARD15 mutations in patients with plaque-type psoriasis and psoriatic arthritis: lack of association. Arch Dermatol Res 2006; 297 (9): 409-411.
40. Plant D, Lear J, Marsland A, et al. CARD15/NOD2 single nucleotide polymorphisms do not confer susceptibility to type I psoriasis. Br J Dermatol 2004; 151 (3): 675-678.
41. Hampe J, Schreiber S, Shaw SH, et al. A genome-wide analysis provides evidence for novel linkages in inflammatory bowel disease in a large European cohort. Am J Hum Genet 1999; 64: 808-816.
42. Oh C, Das K, Gottlieb A,. Treatment with anti-tumor necrosis factor α (TNF-α) monoclonal antibody dramatically decreases the activity of psoriasis lesions. J Am Acad Dermatol 2000; 42: 829-830.
43. Negoro K, Kinouchi Y, Hiwatashi N, et al. Crohn's disease is associated with novel polymorphisms in the 5'-flanking region of the tumor necrosis factor gene. Gastroenterology 1999; 117: 1062-1068.
44. Hohler T, Kruger A, Schneider P, et al. A TNF-α promoter polymorphism is associated with juvenile onset psoriasis and psoriatic arthritis. J Invest Dermatol 1997; 109: 562-564.
45. Enlund F, Samuelsson L, Enerback C, et al. Psoriasis susceptibility locus in chromosome region 3q21 identified in patients from southwest Sweden. Eur J Hum Genet 1999; 7: 783-790.
46. Matthews D, Fry L, Powles A, et al. Evidence that a locus for familial psoriasis maps to chromosome 4q. Nat Genet 1996; 14: 231-233.
47. Cho J, Nicolae D, Gold L, et al. Identification of novel susceptibility loci for inflammatory bowel disease on chromosomes 1p, 3q, and 4q: evidence for epistasis between 1p and IBD1. Proc Natl Acad Sci USA 1998; 95: 7502-7507.
48. Satsangi J, Parkes M, Louis E, et al. Two stage genome-wide search in inflammatory bowel disease provides evidence for susceptibility loci on chromosomes 3, 7, and 12. Nat Genet 1996; 14: 199-200.
49. Quaranta M, Burden AD, Griffiths CE, et al. Differential contribution of CDKAL1 variants to psoriasis, Crohn's disease and type II diabetes. Genes Immun 2009; 10 (7): 654-658.
50. Hollox EJ,. Copy number variation of beta-defensins and relevance to disease. Cytogenet Genome Res 2008; 123: 148-155.
51. Bentley RW, Pearson J, Gearry RB, et al. Association of higher DEFB4 genomic copy number with Crohn's disease. Am J Gastroenterol 2010; 105 (2): 354-359.
52. Korman BD, Kastner DL, Gregersen PK, et al. STAT4: genetics, mechanisms, and implications for autoimmunity. Curr Allergy Asthma Rep 2008; 8 (5): 398-403.
53. Zervou MI, Goulielmos GN, Castro-Giner F, et al. STAT4 gene polymorphism is associated with psoriasis in the genetically homogeneous population of Crete, Greece. Hum Immunol 2009; 70 (9): 738-741.
54. Cargill M, Schrodi SJ, Chang M, et al. A large-scale genetic association study confirms IL 12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet 2007; 80: 273-290.
55. Duerr RH, Taylor KD, Brant SR, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006; 314: 1461-1463.
56. Taurog JD, Lipsky PE,. Ankylosing spondylitis, reactive arthritis, and undifferentiated spondyloarthropathy. In:, Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL, eds. Harrison's Principles of Internal Medicine. New York: McGraw-Hill, 2001; p 1949.
57. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008; 58: 826-850.
58. Gelfand JM, Gladman DD, Mease PJ, et al. Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol 2005; 53: 573.
59. Liu Y, Helms C, Liao W, et al. A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. PLoS Genet 2008; 4: e1000041.
60. Duffin KC, Woodcock J, Krueger GG,. Genetic variations associated with psoriasis and psoriatic arthritis found by genome-wide association. Dermatol Ther 2010; 23 (2): 101-113.
61. Orchard TR,. Extraintestinal manifestations: skin, joint and mucocutaneous manifestations. In:, Satsangi J, Sutherland LR, eds. Inflammatory Bowel Disease, Chpater 43. Churchill Livingstone: Elsevier Limited, 2003: 669-684.
62. Mielants H, Veys EM, De Vos M, et al. The evolution of spondyloarthropathies in relation to gut histology. I Clinical aspects. J Rheumatol 1995; 22: 2266-2272.
63. Mielants H, Veys EM, Cuvelier C, et al. The evolution of spondyloarthropathies in relation to gut histology. II. Histological aspects. J Rheumatol 1995; 22: 2273-2278.
64. Colombo E, Latiano A, Palmieri O, et al. Enteropathic spondyloarthropathy: a common genetic background with inflammatory bowel disease? World J Gastroenterol 2009; 20: 2456-2462.
65. Rath HC, Herfarth HH, Ikeda JS, et al. Normal luminal bacteria, especially Bacteroides species, mediate chronic colitis, gastritis, and arthritis in HLA-B27/human beta2 microglobulin transgenic rats. J Clin Invest 1996; 98: 945-953.
66. Taurog JD, Richardson JA, Croft JT, et al. The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med 1994; 180: 2359-2364.
67. Bumpstead S, Prescott NJ, Nimmo ER, et al. Genetic determinants of ulcerative colitis include the ECM1 locus and five loci implicated in Crohn's disease. Nat Genet 2008; 40: 710-712.
68. Crane AM, Bradbury L, van Heel DA, et al. Role of NOD2 variants in spondylarthritis. Arthritis Rheum 2002; 46: 1629-1633.
69. Hoffmann R, Schieferstein G, Schunter F, et al. Increased occurrence of psoriasis in patients with Crohn's disease and their relatives. Am J Gastroenterol 1991; 86: 787-788.
70. Scarpa R, Manguso F, D'Arienzo A, et al. Microscopic inflammatory changes in colon of patients with both active psoriasis and psoriatic arthritis without bowel symptoms. J Rheumatol 2000; 27: 1241-1246.
71. Ott SJ, Musfeldt M, Wenderoth DF, et al. Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease. Gut 2004; 53 (5): 685-693.
72. Naser SA, Ghobrial G, Romero C, et al. Culture of Mycobacterium avium subspecies paratuberculosis from the blood of patients with Crohn's disease. Lancet 2004; 364 (9439): 1039-1044.
73. Norrlind R,. Significance of infection in origin of Psoriasis. Acta Rheumatol Scand 1955; 1: 135-144.
74. Osterlund A, Popa R, Nikkila T, et al. Intracellular reservoir of Streptococcus pyogenes in vivo: a possible explanation for recurrent pharyngotonsillitis. Laryngoscope 1997; 107: 640-647.
75. Molinari G, Chhatwal GS,. Streptococcal invasion. Curr Opin Microbiol 1999; 2: 56-61.
76. Diluvio L, Vollmer S, Besgen P, et al. Identical TCR beta-chain rearrangements in streptococcal angina and skin lesions of patients with psoriasis vulgaris. J Immunol 2006; 11: 7104-7111.
77. Elder JT, Nair RP, Guo SW, Henseler T, Christophers E, Voorhees JJ,. The genetics of psoriasis. Arch Dermatol 1994; 130: 216-224.
78. Johnston A, Gudjonsson JE, Sigmundsdottir H, Love TJ, Valdimarsson H,. Peripheral blood T cell responses to keratin peptides that share sequences with streptococcal M proteins are largely restricted to skin-homing CD8+ T cells. Clin Exp Immunol 2004; 138: 83-93.
79. Tomi NS, Kranke B, Aberer E,. Staphylococcical toxin in patient with psoriasis, atopic dermatitis and erythroderma, and in healthy control subjects. J Am Acad Dermatol 2005; 53: 67-72.
80. Franchi L, Kanneganti TD, Dubyak GR, et al. Differential requirement of P2X7 receptor and intracellular K+ for caspase-1 activation induced by intracellular and extracellular bacteria. J Biol Chem 2007; 26: 18810-18818.
81. Farr PM, Krause LB, Marks JM, et al. Response of scalp psoriasis to oral ketoconazole. Lancet 1985; 2: 921-922.
82. Bunse T, Mahrle G,. Soluble Pityrosporum-derived chemoattraccant for polymorphonuclear leukocytes of psoriasic patients. Acta Derm Venereol 1996; 76: 10-12.
83. Lu Q, Jayatilake JA, Samaranayake LP, et al. Hyphal invasion of Candida albicans inhibits the expression of human beta-defensins in experimental oral candidiasis. J Invest Dermatol 2006; 126: 2049-2056.
84. Vonk AG, Netea MG, van Krieken JH, et al. Endogenous interleukin (IL)-1 alpha and IL-1 beta are crucial for host defense against disseminated candidiasis. J Infect Dis 2006; 193: 1419-1426.
85. Mencacci A, Bacci A, Cenci E, et al. Interleukin 18 restores defective Th1 immunity to Candida albicans in caspase 1-deficient mice. Infect Immun 2000; 68: 5126-5131.
86. Hise AG, Tomalka J, Ganesan S, et al. An essential role for the NLRP3 inflammasome in host defense against the human fungal pathogen Candida albicans. Cell Host Microbe 2009; 5: 487-497.
87. Walsh P, Norris DA, Abe J, et al. Candida albicans induces selective expansion of human T lymphocytes expressing the T-cell receptor variable region V beta 5.1. J Dermatol Sci 1996; 12: 140-146.
88. Majewski S, Favre M, Orth G, et al., Is Human Papilloma virus type 5 the putative antigen involved in Psoriasis? J Invest Dermatol 1998; 111: 541-542.
89. De Socio G, Simonetti S, Stagni G,. Clinical improvement of Psoriasis in an AIDS patient effectively treated with combination antiretroviral therapy. Scand J Infect Dis 2006; 38: 74-75.
90. Backer BS, Owles AVP, Fry L,. A possible role for vaccination in the treatment of psoriasis? G Ital Dermatol Venereol 2008; 143: 105-117.